Piramal Pharma Ltd

BSE
PPLPHARMA •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or open an account for live prices.
Start SIP in Piramal Pharma Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
72.69% Gain from 52W Low
8.9
TTM PE Ratio
High in industry
1124.2
Price to Book Ratio
Below industry Median
2.5
Dividend yield 1yr %
Low in industry
0.1
TTM PEG Ratio
PEG TTM is much higher than 1
10.3
RSI
RSI is mid-range
43.5
MFI
MFI is mid-range
32.9

Piramal Pharma Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Piramal Pharma Ltd shareholding Pattern

Promoter
35%
Foreign Institutions
30.6%
Mutual Funds
9%
Domestic Institutions
12.1%
Public
21.9%
Promoter
35%
Foreign Institutions
32.5%
Mutual Funds
6.3%
Domestic Institutions
9.7%
Public
22.4%
Promoter
35%
Foreign Institutions
32.4%
Mutual Funds
3.8%
Domestic Institutions
8%
Public
24.2%
Promoter
34.8%
Foreign Institutions
35%
Mutual Funds
0.9%
Domestic Institutions
5.5%
Public
24.3%
Promoter
34.8%
Foreign Institutions
39.3%
Mutual Funds
0.5%
Domestic Institutions
5%
Public
20.6%
Promoter
34.8%
Foreign Institutions
41.3%
Mutual Funds
0.5%
Domestic Institutions
5.3%
Public
18.3%

Piramal Pharma Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
5
Bearish Moving Averages
11
5Day EMA
153.00
10Day EMA
154.50
12Day EMA
154.80
20Day EMA
154.80
26Day EMA
154.30
50Day EMA
151.40
100Day EMA
145.10
200Day EMA
135.00
5Day SMA
153.00
10Day SMA
155.90
20Day SMA
156.30
30Day SMA
154.40
50Day SMA
152.60
100Day SMA
142.60
150Day SMA
140.70
200Day SMA
132.40
Delivery & Volume
Resistance & Support
151.18
Pivot
Resistance
First Resistance
152.37
Second Resistance
153.63
Third Resistance
154.82
Support
First Support
149.92
Second support
148.73
Third Support
147.47
Relative Strength Index
43.51
Money Flow Index
32.90
MACD
0.41
MACD Signal
1.56
Average True Range
4.40
Average Directional Index
20.93
Rate of Change (21)
-1.83
Rate of Change (125)
5.37
Peer comparison
Compare
Company
Market Price
Market Cap
52W Low
52W High
Alembic Pharmaceuticals Ltd.
19353.61
641.65
1093.05
AstraZeneca Pharma India Ltd.
16890.13
3715.05
7550
Natco Pharma Ltd.
21212.88
672.7
1259.45
Pfizer Ltd.
22196.11
3731.05
5050
Sanofi India Ltd.
14691.64
5850.55
10526.05
Suven Pharmaceuticals Ltd.
21606.2
471
889

Piramal Pharma Ltd Company background

Founded in: 2020
Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through endtoend manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling overthecounter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. Piramal Pharma Solution provides integrated drug discovery, development, and manufacturing services for both drug substances, i.e. active pharmaceutical ingredients (APIs) and drug products, i.e. formulations across the life cycle of a molecule, from discovery and clinical development to commercial launch. In addition, the Company has a joint venture (Allergan India Private Limited) with Allergan(now AbbVie), one of the market leaders in ophthalmology in the Indian formulations market. PPL holds 49% of the paidup equity share capital in the joint venture. Further, PPL has a minority investment of 33.33% in Yapan Bio that operates in the biologics/ biotherapeutics and vaccine segments. The Company is among the leading players in India in the selfcare space, with established brands like Saridon, Supradyn, Lacto Calamine, Littles, Tetmosol, iPill and Polycrol.Apart from this, the Company offers differentiated capabilities in niches areas such as highly potent APIs, antibody drug conjugates, potent sterile injectables, hormonal oral solid dosage forms and biologics and vaccines. It has a global footprint with manufacturing capabilities across 15 facilities spanning across India, US, the UK and Canada. It also has global distribution network in over 100 countries. The Companys global distribution network gives it access to offer services and products to customers including large global pharma companies, biotech companies, hospitals and institutions.In June 2020, the Company acquired pharmaceutical business from Piramal Enterprises Limited (PEL).In October 2020, the Company received growth equity investment from the Carlyle Group. In It acquired 100% stake in Convergence Chemicals Private Limited (CCPL). It announced expansion for antibody drug conjugates at its Grangemouth (UK) facility and expansion of drug substance capabilities at its Riverview facility (USA).In 2021, it acquired Hemmo Pharmaceuticals Private Limited (HPPL), into the development and manufacturing of peptide APIs. On 7th October 2021, the Composite Scheme of Arrangement, which was entered into between the Company, Piramal Pharma Limited (PPL), Convergence Chemicals Private Limited (CCPL), Hemmo Pharmaceuticals Private Limited (HPPL), PHL Fininvest Private Limited (PFPL) and their respective shareholders and creditors for demerger of Pharma Business from Piramal Enterprises Limited (PEL) to PPL, amalgamation of CCPL and HPPL (both being wholly owned subsidiaries of PPL) into PPL and the amalgamation of PFPL (a wholly owned subsidiary of PEL) into PEL was effective from August 18, 2022.In consideration for the demerger, the equity shareholders of PEL as on the demerger record date received 4 equity shares of face and paidup value of Rs 10 each of the Company for every 1 equity share of face and paidup value of Rs 2 each held in PEL. i.e. 4:1. Accordingly, the Company was listed on the Stock Exchanges, BSE Limited (BSE) and National Stock Exchange of India Limited NSE) onOctober 19, 2022. In 2022, the Company acquired minority stake in Yapan Bio Private Limited, an IndiaBased CDMO providing expertise in biologics and vaccines. It launched 26 New products and 37 new SKUs during FY 2023.
Read More

Piramal Pharma Ltd FAQs

The past 1-year return of Piramal Pharma Ltd [PPLPHARMA] share was 66.22. The Piramal Pharma Ltd [PPLPHARMA] share hit a 1-year low of Rs. 87.55 and a 1-year high of Rs. 166.6.

The Mutual Fund Shareholding was 9.01% at the end of .

You can easily buy Piramal Pharma Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -